Coverage for Zolgensma, a multi-million dollar gene-therapy drug used to treat spinal muscular atrophy will now be permanently available in Alberta. The provincial government provided interim coverage for the drug from January to June 2021, but now a long-term agreement has been reached with the manufacturer. As Nicole Stillger reports, eligible babies will now be able to access the drug, before they lose function.
Global News Hour at 6 Edmonton
Multi-million dollar life-saving gene therapy drug Zolgensma permanently added to Alberta drug coverage program
More Videos
-
Long-awaited Trans Mountain pipeline expansion opens
-
Political analyst expects municipal political parties if Bill 20 passes
-
Alberta Municipalities speaks out over province’s Bill 20 to have more control over local politics
-
Alberta’s ‘unprecedented’ Bill 20 raises a lot of questions
-
Alberta to pilot new social studies curriculum after facing blowback
-
Edmonton city councillors call on Danielle Smith for apology on anonymous letter comments
You are viewing an Accelerated Mobile Webpage.
View Original Article